<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1993 and 2000, 24 patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> underwent high-dose chemo/radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Median age was 44 years, median interval from diagnosis to HSCT was 24 months and the median number of prior lines of treatment was three </plain></SENT>
<SENT sid="2" pm="."><plain>Donor source was HLA matched sibling (23) or matched unrelated donor (one) </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning therapy was <z:chebi fb="0" ids="28901">busulfan</z:chebi> based in 22 patients and included total body irradiation in two </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received i.v. <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A and short-course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> for GVHD prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>Nineteen patients are alive, a median of 2.3 years post HSCT </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo> occurred due to transplant complications in four patients and one patient died of a <z:hpo ids='HP_0001297'>stroke</z:hpo> 10 months post HSCT </plain></SENT>
<SENT sid="7" pm="."><plain>No patients have relapsed </plain></SENT>
<SENT sid="8" pm="."><plain>The overall and progression-free survival was 78% (95% CI 63-97) </plain></SENT>
<SENT sid="9" pm="."><plain>Allogeneic HSCT for patients with progressive follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is feasible and may result in prolonged disease-free survival </plain></SENT>
</text></document>